Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction by Sountoulides, Petros et al.
World J Urol (2010) 28:3–8
DOI 10.1007/s00345-009-0480-3
123
TOPIC PAPER
Role of voiding and storage symptoms for the quality of life before 
and after treatment in men with voiding dysfunction
Petros Sountoulides · Marleen M. van Dijk · 
Hessel Wijkstra · Jean J. M. C. H. de la Rosette · 
Martin Christian Michel 
Received: 1 July 2009 / Accepted: 26 September 2009 / Published online: 9 October 2009
© The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract
Purpose Previous studies on associations between void-
ing dysfunction and quality of life (QoL) have largely been
limited to baseline data. Therefore, we have explored asso-
ciations between Qmax and voiding and storage sub-scores
of the International Prostate Symptom Score (IPSS) before
and after treatment with QoL.
Methods Analysis of a single-center database of 2,316
men with voiding dysfunction attributed to benign prostatic
hyperplasia undergoing various medical and surgical treat-
ment forms.
Results Qmax exhibited little correlation with QoL before
or after treatment. IPSS inversely correlated with QoL at
baseline and after treatment, and IPSS improvements corre-
lated with those of QoL. The associations applied to both
the voiding and storage sub-score of the IPSS, with the lat-
ter consistently exhibiting somewhat tighter associations.
Conclusions Our post-treatment data support the idea of a
cause–eVect relationship between voiding symptoms and
QoL irrespective of treatment form. While both voiding and
storage symptoms contribute to this relationship, storage
symptoms play a somewhat greater role.
Keywords Quality of life · Benign prostatic hyperplasia · 
Voiding dysfunction · -Blocker · Transurethral microwave 
thermotherapy · Transurethral resection of the prostate
Introduction
Male voiding dysfunction is common in the general popula-
tion, particularly in the elderly. It is often, although not nec-
essarily rightly so, attributed to the presence of benign
prostatic hyperplasia (BPH). The extent of voiding dys-
function is typically assessed by quantifying signs such as a
reduced peak urinary Xow (Qmax) or symptoms as measured
in the International Prostate Symptom Score (IPSS). Based
upon factor analysis [1], the IPSS is often subdivided into a
voiding and a storage sub-score. Of note, the IPSS is some-
what biased toward voiding symptoms, as four of the seven
question belong to the voiding sub-score. While a patho-
physiological link between BPH and the associated
obstruction and lower urinary tract symptoms (LUTS)
implies mainly the presence of voiding/obstructive symp-
toms, storage/irritative symptoms are also common in such
men [2].
Male LUTS are often associated with a reduced disease-
speciWc quality of life (QoL). This can be assessed by a
variety of questionnaires among which the QoL question of
the IPSS is used most often [3] although more complex
instruments such as the SF-36 questionnaire may be more
informative [4]. Such research shows that a greater IPSS
statistically is strongly associated with a reduced QoL prior
to treatment [5, 6]. Many studies imply that storage symp-
toms may contribute to this reduced QoL to a greater extent
than voiding symptoms across both genders [4, 7–10], even
among men considered to have major obstruction as they
are waiting for BPH-related surgery [11] but limited other
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studies in men report a stronger association of voiding than
storage symptoms with a reduced QoL [12]. Whether a
reduced  Qmax and voiding symptoms as assessed in the
IPSS and its voiding sub-score can be considered equiva-
lent in this regard has not been evaluated thoroughly.
Thus, the existing literature clearly demonstrates an
association of both voiding and storage symptoms with
QoL at baseline, with the latter exhibiting somewhat stron-
ger correlations. However, a cause–eVect relationship is
diYcult to evaluate based upon statistical associations at
baseline alone. Stronger scientiWc arguments could come
from analysis of similar relationships after treatment but
only very limited data on this are available [13]. Even more
importantly, evidence for a cause–eVect relationship could
come from exploring associations between treatment-asso-
ciated changes of voiding and storage sub-scores on the one
and changes of QoL on the other hand. While various treat-
ment forms have consistently shown QoL improvement in
LUTS/BPH patients [14], the relationship between
improvements of voiding and storage sub-scores with those
of QoL, to the best of our knowledge, has not been studied
before. Therefore, the present study was done to primarily
explore such relationships after treatment in a large sample
of men with LUTS/BPH.
Patients and methods
This is a retrospective analysis of a single-center database
generated during routine care at the Dept. of Urology of the
Radboud University Nijmegen Medical Centre (Nijmegen,
Netherlands), which includes patients diagnosed with
LUTS/BPH between 1992 and 2002. The diagnosis and
treatment decisions were not based on formalized criteria
but on the medical judgment of one urologist (JdlR) based
upon digital rectal examination, estimation of prostate
volume by means of transrectal ultrasound, uroXowmetry,
urinalysis and IPSS including its QoL question.
Our analysis of associations at baseline includes all
patients in the database for whom relevant data were avail-
able (n = 2,611). Post-treatment analyses are based on
patients with at least one assessment of the IPSS 6–
12 months after initiation of treatment where at least 150
patients were available for a given form of treatment. This
time frame was chosen because it should yield a reasonably
stable post-treatment situation. The following interventions
yielded suYcient patient numbers for further analysis:
watchful waiting (WW, n = 421),  -blockers (n = 297),
transurethral microwave thermotherapy (TUMT, n = 356)
and transurethral resection of the prostate (TURP, n = 184).
This excluded 696 patients because they had received treat-
ments other than the above, and 265, 198, 72 and 122 in the
WW, -blockers, TUMT and TURP groups, respectively,
because no post-treatment data were available. -Blocker
treatment consisted of standard doses of alfuzosin, tamsulo-
sin or terazosin. TUMT was administered with the Prosta-
tron machine (EDAP-TMS, France) on an ambulatory
basis, and TURP was performed under spinal or general
anesthesia. If more than one assessment was done within 6–
12 after initiation of treatment, the results closest to
9 months after initiation were used.
A descriptive analysis of the treatment groups at baseline
and after 6–12 months of treatment is presented as
mean § SD. From the IPSS a voiding sub-score based upon
the symptoms incomplete emptying, intermittency, weak
stream, and straining was calculated and a storage sub-
score based upon frequency, urgency, and nocturia [1]. As
both the voiding and the storage sub-score of the IPSS cor-
related only poorly with Qmax at baseline (r = 0.162 and
0.126, respectively, n = 2611), we have used all three
parameters in parallel as explanatory variables to explore
their relationships with QoL using multiple regression anal-
ysis. SpeciWcally, we have addressed three questions: (1)
What is the statistical association of Qmax and the voiding
and storage sub-score to QoL at baseline and after 6–
12 months of treatment (secondary aim)? (2) Do the various
treatments diVer in their eVects on Qmax, voiding and stor-
age (tertiary aim)? For this analysis, the possibly confound-
ing factors age, and baseline values of the respective
parameter were used as covariates in a multiple regression
analysis. Moreover, the -blocker group was used as the
reference treatment because most data from double-blind,
randomized studies exist for this treatment form which is
known to improve voiding and storage sub-scores to a sim-
ilar extent [15–23]. (3) What is the statistical association of
the treatment-associated alterations of Qmax, voiding and
storage sub-scores to the associated improvement in QoL
score (primary aim)? All statistical analyses were per-
formed with the statistical software SPSS for Windows
(version 11.5.1, SPSS Inc. Chicago, IL, USA.), and a
p < 0.05 was considered as statistically signiWcant.
Results
In multiple regression analysis, baseline Qmax and voiding
and storage sub-scores of the IPSS were signiWcantly but
weakly associated with QoL with the storage sub-score
exhibiting the strongest association among the three
explanatory variables (Table 1). Thus, all other factors
being equal, a Qmax diVerence of 1 ml/s or 1 point in each
sub-score statistically explained only a diVerence of 0.010,
0.074 and 0.120 points in the QoL score.
As expected, patients assigned to WW, -blocker,
TUMT and TURP had diVerent baseline characteristics.
Lower baseline Qmax correlated with increasing invasivenessWorld J Urol (2010) 28:3–8 5
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of treatment chosen, i.e. was highest in the WW and lowest
in the TURP group (Table 2). The voiding and storage sub-
scores at baseline were lower in the WW than in the other
three groups, but no major diVerences were seen between
the latter three.
Increasing invasiveness of treatment was associated with
increasing improvements of Qmax and voiding and storage
sub-scores (Table 2), i.e. all three parameters improved with
an order of eVectiveness of WW < -blocker <TUMT <
TURP. In order to explore in more detail the relationship
between a form of treatment and the extent of improvement
of Qmax and voiding and storage sub-scores, we have applied
multiple regression analysis using age and baseline value of
the respective parameter as co-explanatory variables
(Table 3). This analysis demonstrated small but signiWcant
adverse eVects of age on the improvement of Qmax and the
storage sub-score, whereas improvements of the voiding sub-
score were not signiWcantly aVected. As expected, respective
baseline values had a strong eVect on the improvement of all
three parameters, i.e. each ml/s or point at baseline statisti-
cally explained approximately 0.5 ml/s or 0.6 points of
improvement. Compared to -blocker treatment as the refer-
ence group, WW had rather similar eVects, i.e. they were
numerically slightly weaker than those of the -blocker with
the diVerences reaching statistical signiWcance only for the
voiding sub-score. In contrast, TUMT and even more so
TURP yielded greater beneWt than -blocker treatment. Inter-
estingly, these diVerences were more pronounced for Qmax
and the voiding than for the storage sub-score.
Having characterized the eVects of the various treat-
ments on Qmax and the IPSS sub-scores, we have applied
multiple regression analysis to explore their associations
with QoL after treatment (Table 1). This conWrmed the
associations between all three parameters and QoL already
observed at baseline. Finally, and most importantly, we
have explored our primary research question, i.e. how treat-
ment-associated alterations of Qmax and voiding and storage
sub-scores related to alterations of QoL (Table 1). Improve-
ments of all three parameters were signiWcantly but weakly
associated with QoL improvements. For example, each
treatment-induced change of Qmax by 1 ml/s or the voiding
or storage sub-score by 1 point was associated with changes
of QoL by 0.033, 0.109 and 0.119 points, respectively.
Discussion
The present analysis was primarily designed to explore
whether the hypothesis of LUTS as a cause of reduced QoL
and speciWcally the relative roles of voiding and storage
LUTS can be further supported by post-treatment data.
Critique of methods
For the selection of post-treatment data we have limited
ourselves to patients with at least one assessment at
6–12 months after initiation of treatment to reXect a some-
what stable clinical situation. Moreover, we have limited
ourselves to patients which had received one of the treat-
ment forms for which at least 150 patients were available to
yield meaningful group sizes. Patients with and without fol-
low-up data did not diVer in a meaningful way in their baseline
Table 1 Multiple regression analysis of the relationship between Qmax, voiding and storage score on the one and QoL on the other hand
The analysis is based upon 2,316 and 1,258 patients prior to and 6–12 months after treatment, respectively. Data are given as unstandardized regres-
sion coeYcients with SEM (all p < 0.05) at baseline, after treatment and for the association between Qmax and score changes with those of QoL
Parameter Baseline Post-treatment Change parameter 
vs. change QoL
Qmax, per ml/s ¡0.010 § 0.004 ¡0.016 § 0.004 ¡0.033 § 0.005
Voiding sub-score, per point 0.074 § 0.005 0.107 § 0.007 0.109 § 0.008
Storage sub-score, per point 0.120 § 0.006 0.156 § 0.010 0.119 § 0.012
Table 2 Baseline and post-
treatment characteristics accord-
ing to allocated treatment
Watchful waiting -blocker TUMT TURP
n 421 297 356 184
Age (years) 62.9 § 7.8 62.6 § 8.0 67.1 § 8.1 64.9 § 7.4
Qmax (ml/s) 12.5 § 5.6 10.7 § 5.0 9.3 § 3.3 8.3 § 3.4
+2 § 43% +14 § 53% +80 § 140% +217 § 220%
Voiding sub-score, points 7.8 § 4.3 10.6 § 4.4 10.7 § 4.4 10.9 § 4.4
+2 § 85% ¡28 § 51% ¡60 § 45% ¡85 § 24%
Storage sub-score, points 5.8 § 3.2 7.9 § 3.2 8.3 § 3.3 8.3 § 3.3
¡2 § 69% ¡25 § 41% ¡38 § 49% ¡60 § 30%
Data are mean § SD of the indi-
cated number of patients for 
baseline values and % changes 
thereof upon 6–12 months of 
treatment6 World J Urol (2010) 28:3–8
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values, and all treatment groups had comparable attrition
rates (data not shown). Treatment allocations had been
based upon the clinical judgment of one urologist, yielding
the expected heterogeneity in pre-treatment symptoms
between groups. Where applicable this has been taken
account as co-variables in our analyses, as randomized
comparisons of e.g. WW and TURP would be neither feasi-
ble nor ethical [24].
Our QoL assessments are based upon the QoL question
of the IPSS. While more complex instruments such as the
SF-36 may have beneWts over single-item questionnaires,
the QoL question of the IPSS has been used in the majority
of previous studies in the Weld and consistently shown good
correlations with more complex instruments and hence is
considered to be a valid QoL assessment with major utility
due to its simplicity [14].
Multiple biological mechanisms including degeneration
of the bladder upon long-standing obstruction may contrib-
ute as causes of LUTS and hence QoL, but the present data-
base does not allow this type of analysis.
In line with previous studies [25,  26] our analysis
showed only limited correlation between both voiding or
storage sub-scores with Qmax, and hence Qmax has been
included as a separate item into our analyses. All of these
factors should be taken into account in the interpretation of
our data.
Baseline data
In line with many previous studies [4, 7–11], our baseline
data conWrm that the storage sub-score exhibits a somewhat
stronger association with QoL than the voiding sub-score
and each of them a stronger association than Qmax. The
extent of the diVerence in strength of association between
the voiding and storage sub-scores may even be under-esti-
mated because the IPSS is biased toward voiding symptoms
[1] and hence one point of the storage sub-score is some-
what more diYcult to achieve than one point of the voiding
sub-score. This validates our database and Wndings for the
subsequent analysis of post-treatment data.
Treatment eVects
As expected, the various treatment forms varied consider-
ably in their eYcacy with the more invasive treatments
(TUMT, TURP) causing greater improvement than
-blockers despite similar baseline symptoms. Of note, the
superiority of TUMT and TURP related not only to
the voiding but also, albeit to a slightly smaller extent, to the
storage symptoms. Possible roles of more recent medical
approaches to LUTS, particularly storage LUTS, such as
muscarinic receptor antagonists [27] could not be evaluated
as part of our studies as none of our patients had received
such medication.
A statistical association of two parameters at baseline
provides only very limited evidence for a cause–eVect rela-
tionship. Therefore, the main aim of the present analysis
was to explore the statistical associations of voiding and
storage symptoms with QoL after treatment, and even more
importantly how well improvements in either sub-score
correlate to those of QoL. Very limited earlier Wndings have
indicated that storage symptoms correlate somewhat better
with QoL than voiding symptoms, with Qmax yielding little
association [13]. Our data, based upon multiple treatment
forms with diVerent eYcacy, conWrm those Wndings. Our
data importantly extend those earlier studies by demonstrat-
ing that reductions of both voiding and storage sub-scores
correlate with QoL improvements, with the latter yielding
Table 3 Multiple regression analysis of the relationship between form of treatment and other factors and improvement of the Qmax and voiding
and storage sub-scores of the IPSS
Data are mean § SEM of the unstandardized regression coeYcient and the corresponding p-values. EVects of treatment forms are expressed rela-
tive to those of the reference group (-blocker treatment). This means e.g. that all other factors being equal, 1 year of age explains an improvement
of the storage sub-score by 0.035 points, one point of the voiding sub-score at baseline explains an improvement of this sub-score by 0.675 points,
and that TURP improves the storage sub-score by 2.665 points more than -blocker treatment
Variable Qmax, ml/s Voiding sub-score, points Storage sub-score, points
Age, per year ¡0.083 § 0.022 0.003 § 0.014 0.035 § 0.010
<0.001 0.826 <0.001
Basal value ¡0.452 § 0.037 ¡0.675 § 0.025 ¡0.590 § 0.023
<0.001 <0.001 <0.001
Watchful waiting ¡0.259 § 0.461 0.770 § 0.295 0.303 § 0.208
0.574 0.009 0.145
TUMT 4.222 § 0.480 ¡3.060 § 0.305 ¡1.301 § 0.214
<0.001 <0.001 <0.001
TURP 12.348 § 0.569 ¡5.436 § 0.357 ¡2.665 § 0.250
<0.001 <0.001 <0.001World J Urol (2010) 28:3–8 7
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somewhat tighter associations. As with the baseline data,
the extent of the diVerence in strength of association
between the voiding and storage sub-scores may even be
under-estimated because the IPSS is biased toward voiding
symptoms [1]. In contrast, Qmax shows only little associa-
tion with QoL after treatment.
Conclusions
While many previous studies have demonstrated inverse
correlations between voiding and storage symptoms and
QoL at baseline, our study for the Wrst time shows that
improvements of symptoms correlate with improvements
of QoL. This considerably strengthens the logical assump-
tion that symptoms and QoL are indeed related in a cause–
eVect relationship. Our study also shows that both voiding
and storage symptoms correlate with QoL with the latter
exhibiting slightly tighter correlations, and that such associ-
ation can be found not at baseline but also after treatment.
The relevance of this conclusion is underscored by its
apparent applicability to various medical and surgical treat-
ment forms.
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